



PATENT

16032
#6
12-11-01
P.2.**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Berinstein et al.

Examiner: Unassigned

Serial No.: 09/693,754

Group Art Unit: 1632

Filed: October 20, 2000

Docket: 13115

For: Method of inducing and/or enhancing an immune
Response to tumor antigensRECEIVED
DEC 07 2001
TECH CENTER 160012900

Dated: November 1, 2001

Kalow & Springut LLP
488 Madison Avenue, 19th Fl
New York, NY 10022RECEIVED
DEC 06 2001
TC 1700Assistant Commissioner for Patents
Washington, DC 20231**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. 1.97(b), the attorneys for the Applicants hereby bring to the attention of the Patent and Trademark Office the following documents related to the field of the invention of the application identified above:

I. FOREIGN PATENT DOCUMENTS

<u>PATENT NO.</u>	<u>DATE ISSUED</u>	<u>TITLE</u>
WO 99/02183	21 January 1999	A Method of Inducing a CTL Response
WO 97/47271	18 December 1997	Cellular Vaccines and Immunotherapeutics and Methods for Their Preparation

Certificate of Mailing Under 37 C.F.R. 1.8
I hereby declare that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C.
Date: 11/1/01 Name: J. Colwell

II. NON PATENT PUBLICATIONS

Rao, V.S. et al., "*Partial characterization of two subpopulations of T4 cells induced by active specific intralymphatic immunotherapy in melanoma patients*", Proc. Amer. Assoc. Cancer Research Annual Meeting, vol. 27:325 (1986).

Nestle, Frank O., "*Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells*", Nature Medicine vol. 4:328-332 (1998).

Timmerman, J.M. et al., "*Melanoma vaccines: Prim and proper presentation*", Nature Medicine vol. 4:269-270 (1998).

Mackensen, Andreas et al., "*Homing of intravenously and intralymphatically injected human dendritic cells generated In vitro from CD34+ hematopoietic progenitor cells*", Cancer Immunology Immunotherapy, vol. 48:118-122 (1999).

Irvine, Kari R. et al., "*Recombinant Virus Vaccination against "Self" Antigens Using Anchor-fixed Immunogens*", Cancer Research vol. 59:2536-2540 (1999).

Plotkin, Stanley A., "*General Immunization Practices*", Vaccines Chapter 5, 47-73 (1999).

Sigel, M. B. et al., "*Production of Antibodies by Inoculation into Lymph Nodes*", Methods in Enzymology vol. 93:3-13.

Horig, H. et al., "*Short Analytical Review: Current Issues in Cancer Vaccine Development*" Clinical Immunology Vol. 92, No. 3 pp.211-223 (1999).

The items listed above are identified on Form PTO 1449 which is submitted with this statement. A copy of each of the items identified above is submitted with this statement.

The attorneys for the Applicant take no position on whether or not any item cited above and listed on Form PTO 1449 constitutes prior art against the subject application under any particular provision of Title 35 of the United States Code.

No Office Action on the merits has been received to date for the subject application. It is therefore assumed that no such Office Action has been mailed and that consequently under 37 CFR 1.97(b)(3) no official fee is due for submission of an

information disclosure statement at this time. If an Office Action on the merits has in fact been mailed or if any fee is otherwise required for submission of an information disclosure statement at this time, please charge such fee to deposit account No. 11-0171.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "John J. Santalone", written over a horizontal line.

John J. Santalone
Registration No. 32,794

Telephone: (212) 813-1600
Facsimile: (212) 813-9600